SPOTLIGHT: Up to 100,000 Vioxx claims expected

A federal judge in New Orleans told a gathering of attorneys that there could be as many as 100,000 Vioxx claims when all is said and done. More than 2,000 cases have been filed so far and analysts have pegged Merck's potential liability at about $18 billion. Story

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.